Resveratrol Sensitizes Temozolomide-Resistant Glioblastoma Cells Through Mitogen-Activated Protein Kinase Pathway Inhibition and P-Glycoprotein Modulation
Drug Research · 2025-11 · 75 (09) · 379-385
DOI: 10.1055/a-2698-0203 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Research, online erschienen am 18.11.2025. Verfasst von Maede Rezaie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, Resveratrol, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Glioblastoma multiforme continues to pose a major therapeutic challenge due to its high level of treatment resistance and poor prognosis. Temozolomide is a standard chemotherapeutic agent, but resistance significantly limits its clinical efficacy. This study investigated the potential of resveratrol to overcome temozolomide resistance in glioblastoma cells by examining its effects on molecular mechanisms of drug resistance. Human glioblastoma cell lines U251 and temozolomide-resistant U251/temozolomide were utilized. Cellular viability was assessed using the MTT assay. Molecular mechanisms were evaluated through qRT-PCR, Western blotting, Rhodamine 123 accumulation, and apoptosis detection techniques. The study examined alterations in P-glycoprotein (P-gp) expression, mitogen-activated protein kinase/ERK signaling pathway, and apoptotic markers. Resveratrol significantly reduced the temozolomide resistance of U251/temozolomide cells, lowering the IC50 from 91.89 to 24.5 µM. Combined treatment demonstrated enhanced apoptotic cell death, significant downregulation of P-gp expression and activity, suppression of the mitogen-activated protein kinase/ERK signaling pathway, and upregulation of tumor suppressor miR-647. Resveratrol demonstrates potential as an adjuvant therapy by sensitizing temozolomide-resistant glioblastoma cells through multiple molecular mechanisms. It offers a promising approach to overcome chemotherapeutic resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
- Cognitive and Neuroscience Research Center, Amir-Almomenin Hospital, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
- Solid Tumor Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran.
ORCID-Profile: Bahman Yousefi, Maryam Majidinia
Zitieren
APA
Rezaie, M., Nasehi, M., Shanehbandi, D., Valizadeh, A., Yousefi, B., & Majidinia, M. (2025). Resveratrol Sensitizes Temozolomide-Resistant Glioblastoma Cells Through Mitogen-Activated Protein Kinase Pathway Inhibition and P-Glycoprotein Modulation. Drug Research, 75(09), 379-385. https://doi.org/10.1055/a-2698-0203
Vancouver
Rezaie M, Nasehi M, Shanehbandi D, Valizadeh A, Yousefi B, Majidinia M. Resveratrol Sensitizes Temozolomide-Resistant Glioblastoma Cells Through Mitogen-Activated Protein Kinase Pathway Inhibition and P-Glycoprotein Modulation. Drug Research. 2025;75(09):379-385. doi:10.1055/a-2698-0203
BibTeX
@article{Rezaie2025,
author = {Rezaie, Maede and Nasehi, Mohammad and Shanehbandi, Dariush and Valizadeh, Amir and Yousefi, Bahman and Majidinia, Maryam},
title = {Resveratrol Sensitizes Temozolomide-Resistant Glioblastoma Cells Through Mitogen-Activated Protein Kinase Pathway Inhibition and P-Glycoprotein Modulation},
journal = {Drug Research},
year = {2025},
volume = {75},
number = {09},
pages = {379--385},
doi = {10.1055/a-2698-0203}
}
EUVIMED